Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Investors Of Agenus Inc Are Encouraged To Participate In The Securities Fraud Investigation Led By The Schall Law Firm
08:00pm, Thursday, 08'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Ag
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
09:10am, Thursday, 08'th Aug 2024
Agenus (AGEN) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $4 per share a year ago.
Investors Of Agenus Inc Are Invited To Join The Securities Fraud Investigation Led By The Schall Law Firm
08:30pm, Wednesday, 07'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Ag
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
01:30pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN). Such investors are advised to contac
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
01:15pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN). Such investors are advised to contac
Agenus Publishes Seminal Study on Botensilimab's Activity in Treatment-Resistant Cancers
10:58am, Wednesday, 07'th Aug 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the pre
Investors Of Agenus Inc Can Participate In The Securities Fraud Investigation Conducted By The Schall Law Firm
06:00pm, Tuesday, 06'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Ag
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
02:38pm, Saturday, 03'rd Aug 2024
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN). Such investors are adv
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inve
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
07:20pm, Thursday, 01'st Aug 2024
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are advised to contact
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:06am, Thursday, 01'st Aug 2024
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inve
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inves
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
07:00pm, Tuesday, 30'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN). Such investors are advised to contact
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inves
